Panomifene

Panomifene
Clinical data
Other names	GYKI-13504; EGIS-5650
Identifiers
	IUPAC name 2-[2-[4-[(E)-3,3,3-trifluoro-1,2-diphenylprop-1-enyl]phenoxy]ethylamino]ethanol;
CAS Number	77599-17-8;
PubChem CID	3033654;
ChemSpider	2298282;
UNII	GCW5E728OC;
ChEMBL	ChEMBL2105273;
CompTox Dashboard (EPA)	DTXSID401032965 ;
Chemical and physical data
Formula	C25H24F3NO2
Molar mass	427.467 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1=CC=C(C=C1)/C(=C(/C2=CC=CC=C2)\C(F)(F)F)/C3=CC=C(C=C3)OCCNCCO;
	InChI InChI=1S/C25H24F3NO2/c26-25(27,28)24(21-9-5-2-6-10-21)23(19-7-3-1-4-8-19)20-11-13-22(14-12-20)31-18-16-29-15-17-30/h1-14,29-30H,15-18H2/b24-23+; Key:MHXVDXXARZCVRK-WCWDXBQESA-N;

Panomifene (INN; developmental codes GYKI 13504 and EGIS 5650) is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group related to tamoxifen that was under development as an antineoplastic agent by Egis Pharmaceuticals and IVAX Drug Research Institute in the 1990s for the treatment of breast cancer, but it was never marketed.^[1]^[2]^[3]^[4]^[5]^[6] It reached phase II clinical trials before development was terminated.^[2] The drug was described in 1981.^[1]